

**HIV protease inhibitors****Publication number:** CN1131942**Publication date:** 1996-09-25**Inventor:** DRESSMAN B A (US); FRITZ J E (US); HAMMOND M (US)**Applicant:** AGOURON PHARMACEUTICALS INS (US)**Classification:**

- international: C07D295/20; A61K31/00; A61K31/165; A61K31/40; A61K31/403; A61K31/404; A61K31/435; A61K31/4353; A61K31/4365; A61K31/4427; A61K31/4433; A61K31/445; A61K31/4465; A61K31/47; A61K31/472; A61K31/4725; A61K31/4738; A61K31/4743; A61K31/495; A61K31/535; A61K31/5375; A61K31/675; A61P31/00; A61P31/12; A61P31/18; A61P43/00; C07C237/42; C07C323/42; C07C323/60; C07D207/16; C07D209/08; C07D211/60; C07D211/62; C07D215/48; C07D215/50; C07D217/02; C07D217/06; C07D217/26; C07D401/06; C07D401/12; C07D401/14; C07D403/14; C07D409/12; C07D417/12; C07D495/04; C07F9/12; C07F9/62; C07K5/00; C07D295/00; A61K31/00; A61K31/165; A61K31/40; A61K31/403; A61K31/435; A61K31/4353; A61K31/4427; A61K31/445; A61K31/4465; A61K31/47; A61K31/472; A61K31/4738; A61K31/495; A61K31/535; A61K31/5375; A61K31/675; A61P31/00; A61P43/00; C07C237/00; C07C323/00; C07D207/00; C07D209/00; C07D211/00; C07D215/00; C07D217/00; C07D401/00; C07D403/00; C07D409/00; C07D417/00; C07D495/00; C07F9/00; C07K5/00; (IPC1-7): C07D217/26; C07D401/06; C07D495/04; C07F9/62

- European: C07C237/42; C07C323/60; C07D207/16; C07D209/08; C07D211/60; C07D215/48; C07D215/50; C07D217/02; C07D217/26; C07D401/06; C07D401/12; C07D403/14; C07D409/12; C07D417/12; C07D495/04; C07F9/62

**Application number:** CN19941093534 19941007**Priority number(s):** US19930133543 19931007; US19940190764 19940202; US19930133696 19931007**Also published as:**

WO9509843 (A1)  
EP0722439 (A1)  
US5827891 (A1)  
US5827859 (A1)  
OA10718 (A)  
JP11310573 (A)  
FI961449 (A)  
EP0722439 (A0)  
EE9600091 (A)  
AP600 (A)  
EP0722439 (B1)  
SK284116B (B6)  
SK284115B (B6)  
RU2139280 (C1)  
RO119363 (B1)  
PL185647B (B1)  
NO307050B (B1)  
FI114794B (B)  
ES2236849T (T3)  
ES2181725T (T3)  
DE69434214T (T2)  
CZ290417 (B6)  
CN1195737C (C)  
BG62567 (B1)  
AU694746B (B2)

less &lt;&lt;

**Report a data error he**

Abstract not available for CN1131942

Abstract of corresponding document: **US5827891**

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.